Trial reportJournal of the International AIDS Society2026
Understanding Adolescent Anti-Retroviral Therapy Use in the BREATHER-Plus Trial: Qualitative Findings From South Africa and Uganda.
Trial report in Journal of the International AIDS Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding Adolescent Anti-Retroviral Therapy Use in the BREATHER-Plus Trial: Qualitative Findings From South Africa and Uganda.Journal of the International AIDS Society · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionThe BREATHER-Plus trial was an open-label, randomized non-inferiority trial comparing weekends off antiretroviral therapy (ART) (short cycle therapy [SCT]) with daily oral ART (continuous therapy [CT]) for adolescents aged 12-19 years. We present findings from the qualitative sub-study on the factors influencing trial participants' decisions to take/not take ART in accordance with their randomized arm.
methodsQualitative data collection was conducted in South Africa and Uganda from December 2022 to July 2024 using in-depth interviews (IDIs) and focus group discussions (FGDs). We purposively recruited 29 trial participants (14 SCT/15 CT arm) to take part in IDIs in South Africa. From the trial sites in both countries, 47 trial participants, 17 non-trial participants, 15 caregivers and 16 healthcare providers took part in FGDs. Data collection with trial participants focused on adherence to SCT compared to daily ART; the acceptability of SCT and the experience of taking part in the trial. All FGDs explored the feasibility of SCT and preferences for alternative approaches to accessing therapy. Data were analysed thematically.
resultsBoth IDI and FGD data showed that the opportunity to have weekends off from treatment was welcomed by participants, caregivers and healthcare providers. However, the understanding of "2 days off" treatment was interpreted flexibly by some participants. Trial participants in both arms described their fluctuating adherence practices both prior to and during the trial. The introduction of SCT as a possibility through the trial prompted some to talk about previously concealed missed doses. Participants reported that they only mentioned missed doses in the clinic if they had a raised viral load result or had returned to the clinic with too many pills. Many participants relied on their viral load result to confirm that non-adherent behaviour was not problematic.
conclusionsOur findings offer insights into the factors that shape ART adherence among adolescents living with HIV. Adherence is not a static behaviour but a socially embedded and relational practice, shaped by adolescents' interpretations of treatment, interpersonal relationships and the structure of care environments. Regimen modification alone does not resolve the broader social and emotional challenges adolescents face.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.